BioCentury | May 25, 2018
Emerging Company Profile

Universal ambitions

...is using to deliver synthetic versions of the peptides. According to CEO and CSO Thomas Rademacher...
...of development. Sanofi has said the vaccine cost about €1.5 billion ($1.8 billion) to develop. Rademacher...
...nanoparticle candidates in post-infectious blood to select the ones that trigger the strongest immune responses. Rademacher...
BioCentury | Dec 19, 2013
Cover Story

Oral nanoparticles

...any unconjugated linkers on the surface that could cause an immune response," he said. Thomas Rademacher...
BioCentury | Jul 26, 2010
Product Development

Gold-plating Antigens

...invading pathogen by displaying bacterial cell surface proteins, such as toll-like receptor (TLR) ligands. Thomas Rademacher...
...of adjuvant and antigen because the latter approach results in the adjuvant diffusing away. Thus, Rademacher...
...are associated with toxicity due to excessive release of chemokines and cytokines, he said. Similarly, Rademacher...
BioCentury | Apr 14, 2003
Company News

Rodaris, SR Pharma deal

...full ownership of Innopeg, a 2002 joint venture formed with Rodaris. Also, SPA acquired from Rodaris...
...diseases, diabetes, and obesity to diagnose preeclampsia. SPA intends to outlicense some of the molecules. Rodaris Pharmaceuticals Ltd....
BioCentury | Apr 2, 2001
Company News

Rademacher, SR Pharma deal

...assigned patent rights covering IPGs and hormone and growth factor mimetics to the joint venture. Rademacher...
BioCentury | Mar 27, 2001
Company News

SPA and IPG deal

...SR Pharma (LSE:SPA) and the Rademacher Group (Oxford, U.K.) set up a 50:50 joint venture to...
BioCentury | Nov 20, 2000
Financial News

Rademacher raises 8.6 million

Rademacher (Oxford, U.K.) raised 8.6 million ($12.5 million) in a venture financing. Investors included Johnson & Johnson Development; Northern Ventures; Apax; and Advent Venture Partners. The company is developing therapeutics based on a class of...
BioCentury | Jan 19, 1998
Company News

Hoeft Rademacher Ltd. management update

...Hoeft Rademacher Ltd., London, U.K. Business: Metabolic Hired: Sijmen de Vries as CEO, formerly director, market...
BioCentury | Oct 20, 1997
Finance

European private rounds

...Partners EuroGene £0.25M Anglo-Finnish start-up in cardiovascular diseases attracts seed financing from Merlin Ventures Hoeft Rademacher...
BioCentury | Oct 13, 1997
Finance

Burgeoning Euro venture funds

...practicing this approach, this year taking the lead in a couple of deals - Hoeft Rademacher...
Items per page:
1 - 10 of 10
BioCentury | May 25, 2018
Emerging Company Profile

Universal ambitions

...is using to deliver synthetic versions of the peptides. According to CEO and CSO Thomas Rademacher...
...of development. Sanofi has said the vaccine cost about €1.5 billion ($1.8 billion) to develop. Rademacher...
...nanoparticle candidates in post-infectious blood to select the ones that trigger the strongest immune responses. Rademacher...
BioCentury | Dec 19, 2013
Cover Story

Oral nanoparticles

...any unconjugated linkers on the surface that could cause an immune response," he said. Thomas Rademacher...
BioCentury | Jul 26, 2010
Product Development

Gold-plating Antigens

...invading pathogen by displaying bacterial cell surface proteins, such as toll-like receptor (TLR) ligands. Thomas Rademacher...
...of adjuvant and antigen because the latter approach results in the adjuvant diffusing away. Thus, Rademacher...
...are associated with toxicity due to excessive release of chemokines and cytokines, he said. Similarly, Rademacher...
BioCentury | Apr 14, 2003
Company News

Rodaris, SR Pharma deal

...full ownership of Innopeg, a 2002 joint venture formed with Rodaris. Also, SPA acquired from Rodaris...
...diseases, diabetes, and obesity to diagnose preeclampsia. SPA intends to outlicense some of the molecules. Rodaris Pharmaceuticals Ltd....
BioCentury | Apr 2, 2001
Company News

Rademacher, SR Pharma deal

...assigned patent rights covering IPGs and hormone and growth factor mimetics to the joint venture. Rademacher...
BioCentury | Mar 27, 2001
Company News

SPA and IPG deal

...SR Pharma (LSE:SPA) and the Rademacher Group (Oxford, U.K.) set up a 50:50 joint venture to...
BioCentury | Nov 20, 2000
Financial News

Rademacher raises 8.6 million

Rademacher (Oxford, U.K.) raised 8.6 million ($12.5 million) in a venture financing. Investors included Johnson & Johnson Development; Northern Ventures; Apax; and Advent Venture Partners. The company is developing therapeutics based on a class of...
BioCentury | Jan 19, 1998
Company News

Hoeft Rademacher Ltd. management update

...Hoeft Rademacher Ltd., London, U.K. Business: Metabolic Hired: Sijmen de Vries as CEO, formerly director, market...
BioCentury | Oct 20, 1997
Finance

European private rounds

...Partners EuroGene £0.25M Anglo-Finnish start-up in cardiovascular diseases attracts seed financing from Merlin Ventures Hoeft Rademacher...
BioCentury | Oct 13, 1997
Finance

Burgeoning Euro venture funds

...practicing this approach, this year taking the lead in a couple of deals - Hoeft Rademacher...
Items per page:
1 - 10 of 10